In vitro and in vivo inhibitory effects of glycyrrhetinic acid on cytochrome P450 3A activity

Pharmacology

Volumn 86, Issue 5-6, 2010, Pages 287-292

  Li, Hai Yun ^a   Xu, Wen ^b   Su, Juan ^a   Zhang, Xi ^a   Hu, Li Wei ^a   Zhang, Wei Dong ^a,c,d  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d NONE   (China)

Author keywords

Cytochrome P450 3A; Glycyrrhetinic acid; Inhibitory interaction

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A4; GLYCYRRHETINIC ACID; MIDAZOLAM; RECOMBINANT ENZYME;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT;

ANIMALS; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INHIBITORS; GLYCYRRHETINIC ACID; HALF-LIFE; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MIDAZOLAM; RATS; RATS, WISTAR; REGRESSION ANALYSIS;

EID: 77958598518     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320956     Document Type: Article

References (19)

1. Kent UM, Aviram M, Rosenblat M, Hollenberg PF: The licorice root-derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9. Drug Metab Dispos 2002; 30: 709-715.
2. Salvi M, Fiore C, Armanini D, Toninello A: Glycyrrhetinic acid-induced permeability transition in rat liver mitochondria. Biochem Pharmacol 2003; 66: 2375-2379. (Pubitemid 37456745)
3. Lee CS, Kim YJ, Lee MS, Han ES, Lee SJ: 18β- - glycyrrhetinic acid induces apoptotic cell death in SiHa cells and exhibits a synergistic effect against antibiotic anti-cancer drug toxicity. Life Sci 2008; 83: 481-489.
4. Isbrucker RA, Burdock GA: Risk and safety assessment on the consumption of licorice root ( Glycyrrhiza sp), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regul Toxicol Pharmacol 2006; 46: 167-192.
5. Asl MN, Hosseinzadeh H: Review of pharmacological effects of Glycyrrhiza sp and its bioactive compounds. Phytother Res 2008; 22: 709-724.
6. Curreli F, Friedman-Kien AE, Flore O: Glycyrrhizic acid alters Kaposi sarcoma-associated herpesvirus latency, triggering p53-mediated apoptosis in transformed B lymphocytes. J Clin Invest 2005; 115: 642-652.
7. Ohtake N, Kido A, Kubota K, Tsuchiya N, Morita T, Kase Y, Takeda S: A possible involvement of 3-monoglucuronyl-glycyrrhetinic acid, a metabolite of glycyrrhizin (GL), in GL-induced pseudoaldosteronism. Life Sci 2007; 80: 1545-1552.
8. Casabar RC, Wallace AD, Hodgson E, Rose RL: Metabolism of endosulfan-α by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4. Drug Metab Dispos 2006; 34: 1779-1785.
9. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, Downey A, Mudra D, Graham R, Carroll K, Xie J, Madan A, Parkinson A, Christ D, Selling B, LeCluyse E, Gan LS: CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002; 30: 795-804.
10. Moon YJ, Wang X, Morris ME: Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro 2006; 20: 187-210.
11. Quintieri L, Palatini P, Nassi A, Ruzza P, Floreani M: Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP3A4 and CYP3A5 enzymes. Biochem Pharmacol 2008; 75: 1426-1437.
12. Wang RW, Newton DJ, Liu N, Atkins WM, Lu AY: Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate- dependent. Drug Metab Dispos 2000; 28: 360-366.
13. Gibbs MA, Thummel KE, Shen DD, Kunze KL: Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of K i values and impact of CYP3A5 expression. Drug Metab Dispos 1999; 27: 180-187.
14. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE: Characterization of interintestinal and intraintestinal variations in human CYP3Adependent metabolism. J Pharmacol Exp Ther 1997; 283: 1552-1562.
15. Tateishi T, Watanabe M, Moriya H, Yamaguchi S, Sato T, Kobayashi S: No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem Pharmacol 1999; 57: 935-939.
16. Tsukamoto S, Aburatani M, Yoshida T, Yamashita Y, El Beih AA, Ohta T: CYP3A4 inhibitors isolated from licorice. Biol Pharm Bull 2005; 28: 2000-2002.
17. Dixon M, Webb EC: Enzyme, ed 2. London, Longmans, 1964.
18. Kenworthy KE, Clarke SE, Andrews J, Houston JB: Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos 2001; 29: 1644-1651.
19. Spinks EA, Fenwick GR: The determination of glycyrrhizin in selected UK liquorice products. Food Addit Contam 1990; 7: 769-778.